Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis

March 7, 2011 By Bio-Medicine.Org

WASHINGTON, March 7, 2011 /PRNewswire/ — RainDance
Technologies, Inc. and Ambry Genetics, today announced a new
collaboration focused on the development and commercialization of a
comprehensive drug absorption, distribution, metabolism, and
excretion (ADME) genetic screening panel for use on next-generation
sequencing (NGS) systems. The announcement was made in conjunction
with the Society of Toxicology’s 50th Annual Meeting in Washington,
D.C. Financial terms were not disclosed.

(Logo:  http://photos.prnewswire.com/prnh/20110307/LA59848LOGO)

ADME analysis is a critical part of the drug discovery and
development process, providing important data on how a compound
reaches the blood stream and whether distribution, metabolism and
excretion are affected by factors such as age, sex, ethnicity or
genetics. In recent years, the biotechnology and pharmaceutical
industries have been performing ADME screening earlier in an effort
to reduce the significant costs associated with failed drug trials
and hospitalizations due to adverse events. Scientific studies
indicate that more effective indicators of atypical drug metabolism
and molecular pharmacology could help reduce hospitalizations
associated with adverse drug events by 50 percent or
more.(1),(2)

Current genotyping tools for ADME research lack the genetic
sensitivity, genomic coverage, and resolution necessary to detect
many of the important mutations associated with adverse drug
events. The new ADME panel developed by RainDance and Ambry will
provide scientists with the capacity to perform sequence analysis
of entire coding regions associated with more than 220 key drug
metabolism-linked genes including transporters, receptors,
regulators and all pharmacodynamics and pharmacogenetic genes, as
well as all U.S. Federal Drug Administration (FDA)-identified
pharmacogenomic biomarker genes.(3)

“Scientists interested in an

‘/>”/>

SOURCE

Related Articles Read More >

Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech